Pacific Biosciences of California (PACB)

PacBio is best known for long-read sequencing, a method that can capture extended stretches of DNA and reveal genetic variation that may be difficult to detect with shorter-read technologies. Long reads can be useful for identifying structural variants, resolving complex regions of the genome, assembling new genomes, and studying epigenetic signals. The company’s instruments, consumables, software, and analytical tools form an integrated workflow for laboratories that need high-quality genetic analysis.

The business operates as a single reportable segment centered on the development, manufacture, and sale of sequencing platforms and related products. Revenue comes from instrument placements, recurring consumables used in sequencing runs, service, and support. Its customer base includes academic institutions, government research centers, clinical laboratories, pharmaceutical companies, and agricultural genomics organizations.

PacBio competes in a rapidly evolving genomics market where performance, cost per sample, throughput, accuracy, and ease of use are critical. Investors typically follow the company’s adoption rates, new product launches, consumables pull-through, gross margin trends, cash position, and the pace at which long-read sequencing gains broader use in research and translational medicine.